Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa.

IF 4.5 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2025-10-10 DOI:10.1128/aac.00857-25

Kaan Kocer, Truong Nhat My, Bui Tien Sy, Lisa Göpel, Thirumalaisamy P Velavan, Le Huu Song, Silke Peter, Sébastien Boutin, Adesola Olalekan, Dennis Nurjadi

引用次数: 0

Abstract

We evaluated the in vitro activity of cefiderocol in combination with either taniborbactam or xeruborbactam against cefiderocol-resistant, bla_NDM-positive Pseudomonas aeruginosa clinical isolates from Vietnam and Nigeria. Taniborbactam restored cefiderocol susceptibility in most isolates (20/21, 95.2%), while xeruborbactam had no effect. Resistance was reversed by dipicolinic acid, which confirmed New-Delhi Metallo-β-Lactamase (NDM-mediated) resistance. One isolate that was unresponsive to taniborbactam carried multiple copies of bla_NDM-1. These findings highlight the species-specific limitations of xeruborbactam in P. aeruginosa.

查看原文本刊更多论文

头孢地罗与次鲁巴坦联合治疗耐头孢地罗耐药ndm铜绿假单胞菌的疗效比较。

我们评估了头孢地罗与taniborbactam或xeruborbactam联合对头孢地罗col耐药、blandm阳性铜绿假单胞菌临床分离株的体外活性。大多数分离株（20/21,95.2%）对他波巴坦恢复头孢地罗的敏感性，而对希鲁巴坦没有影响。二吡啶酸逆转了耐药，证实了ndm介导的新德里金属β-内酰胺酶（New-Delhi metallic -β-Lactamase, ndm）耐药。一株对坦尼波巴坦无反应的分离株携带多个blaNDM-1拷贝。这些发现突出了铜绿假单胞菌中xuborbactam的物种特异性局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.